SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Hankey Graham J.)
 

Search: WFRF:(Hankey Graham J.) > (2017) > The FOCUS, AFFINITY...

  • Graham, C. (author)

The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke : Statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • 2017-12-28
  • BioMed Central Ltd.2017
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:kth-227107
  • https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-227107URI
  • https://doi.org/10.1186/s13063-017-2385-6DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:137382488URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-348519URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • QC 20180515
  • Background: Small trials have suggested that fluoxetine may improve neurological recovery from stroke. FOCUS, AFFINITY and EFFECTS are a family of investigator-led, multicentre, parallel group, randomised, placebo-controlled trials which aim to determine whether the routine administration of fluoxetine (20 mg daily) for six months after an acute stroke improves patients' functional outcome. Methods/Design: The core protocol for the three trials has been published (Mead et al., Trials 20:369, 2015). The trials include patients aged 18 years and older with a clinical diagnosis of stroke and persisting focal neurological deficits at randomisation 2-15 days after stroke onset. Patients are randomised centrally via each trials' web-based randomisation system using a common minimisation algorithm. Patients are allocated fluoxetine 20 mg once daily or matching placebo capsules for six months. The primary outcome measure is the modified Rankin scale (mRS) at six months. Secondary outcomes include: living circumstances; the Stroke Impact Scale; EuroQol (EQ5D-5 L); the vitality subscale of the 36-Item Short Form Health Survey (SF36); diagnosis of depression; adherence to medication; serious adverse events including death and recurrent stroke; and resource use at six and 12 months and the mRS at 12 months. Discussion: Minor variations have been tailored to the national setting in the UK (FOCUS), Australia, New Zealand and Vietnam (AFFINITY) and Sweden (EFFECTS). Each trial is run and funded independently and will report its own results. A prospectively planned individual patient data meta-analysis of all three trials will provide the most precise estimate of the overall effect and establish whether any effects differ between trials or subgroups. This statistical analysis plan describes the core analyses for all three trials and that for the individual patient data meta-analysis. Recruitment and follow-up in the FOCUS trial is expected to be completed by the end of 2018. AFFINITY and EFFECTS are likely to complete follow-up in 2020.

Subject headings and genre

  • MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Neurologi hsv//swe
  • MEDICAL AND HEALTH SCIENCES Clinical Medicine Neurology hsv//eng
  • Antidepressants
  • Depression
  • Fluoxetine
  • Haemorrhagic stroke
  • Ischaemic stroke
  • Recovery
  • SSRI
  • acute coronary syndrome
  • algorithm
  • Article
  • automutilation
  • brain hemorrhage
  • brain ischemia
  • cerebrovascular accident
  • clinical protocol
  • cognition
  • death
  • drug effect
  • falling
  • fracture
  • functional status
  • gastrointestinal hemorrhage
  • health economics
  • health status
  • human
  • hyperglycemia
  • hypoglycemia
  • hyponatremia
  • medication compliance
  • meta analysis
  • mood
  • neurologic disease
  • outcome assessment
  • quality of life
  • Rankin scale
  • recurrent disease
  • seizure
  • Short Form 36
  • side effect
  • suicide attempt
  • survival
  • treatment duration
  • treatment outcome
  • upper gastrointestinal bleeding

Added entries (persons, corporate bodies, meetings, titles ...)

  • Lewis, S. (author)
  • Forbes, J. (author)
  • Mead, G. (author)
  • Hackett, M. L. (author)
  • Hankey, G. J. (author)
  • Gommans, J. (author)
  • Nguyen, H. T. (author)
  • Lundström, Erik,1964-Uppsala universitet,Karolinska Institutet,Neurologi,Karolinska Inst, Dept Clin Neurosci Neurol, Stockholm, Sweden(Swepub:uu)erlun676 (author)
  • Isaksson, E.Karolinska Institutet (author)
  • Näsman, Per,1954-KTH(Swepub:kth)u1ghoqwp (author)
  • Rudberg, A. -SKarolinska Institutet (author)
  • Dennis, M. (author)
  • Karolinska InstitutetNeurologi (creator_code:org_t)

Related titles

  • In:Trials: BioMed Central Ltd.18:11745-6215

Internet link

Find in a library

  • Trials (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view